A Phase III Open Label, Randomized, 2 Arm Study of Ixabebepilone Administered Every 21 Days vs Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Ednometrial cancer Who Have Previously Been Treated With Chemotherapy
|Effective start/end date||6/30/09 → 6/30/13|
- BRISTOL-MYERS SQUIBB PHARM RES
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.